A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
While a framework to end the war in Iran appears to be in place, disruptions to the global pharma supply chain and the resultant spike in API prices, will mean that pharmaceutical firms will need to navigate turbulent waters, at least in the near term, a senior industry executive in India told Scrip.
in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Learn more about how China’s biopharmas are going global by working with dependable and trustworthy companion diagnostics partners.
China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.
